Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance

BACKGROUND: Cyclin-dependent kinases (CDKs) control cell cycle progression, RNA transcription and apoptosis, making them attractive targets for anticancer drug development. Unfortunately, CDK inhibitors developed to date have demonstrated variable efficacy. METHODS: We generated drug-resistant cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaliszczak, M, Patel, H, Kroll, S H B, Carroll, L, Smith, G, Delaney, S, Heathcote, D A, Bondke, A, Fuchter, M J, Coombes, R C, Barrett, A G M, Ali, S, Aboagye, E O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817326/
https://www.ncbi.nlm.nih.gov/pubmed/24071597
http://dx.doi.org/10.1038/bjc.2013.584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817326/
https://www.ncbi.nlm.nih.gov/pubmed/24071597
http://dx.doi.org/10.1038/bjc.2013.584

Ejemplares similares